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BACKGROUND Up to the present, preload reduction in congestive
heart failure (CHF) patients is performed with high potency diuretics.
Last year, we reported in TCT/ACC 2014 the hemodynamic changes of
the ﬁrst CHF case in humans, using Percutaneous Transluminal Caval
ﬂow Restriction (PTCR) procedure achieved with caval counter-
pulsation balloon (CCPB). This innovative method reduced preload in
CHF. In this study we are reporting the results of the 6 consecutive
patients with CHF, treated with intermittent preload reduction of
caval ﬂow with CCPB, guided by the respiratory phases.
METHODS 6 patients with CHF who met our protocol criteria, were
evaluated. 4 were ischemic, and 2 non ischemic. The mean age was 58
 9. 4 male mean age 55  6 years, and 2 female mean age 63  4. We
performed baseline Doppler echocardiography, coronary angiography
and right heart catheterization. Subsequently caval ﬂow restriction
was started, through the right femoral vein, catheter balloon was
introduced in the femoral vein and echo guided, placed just before
hepatic vein drainage. The balloon was inﬂated according to previous
calculations, to cover Inferior Vena Cava (IVC) remaining area
completing 100% (total occlusion), and 70% during expiration (sub-
occlusion), assuming 30% inspiratory collapse, resulting intermittent
ﬂow. The balloon was kept inﬂated for 30 minutes, right catheteri-
zation and echocardiography were repeated during inﬂated balloon.
The balloon was removed and deﬂated.
RESULTS Table 1. Hemodynamic Variables. Graphic 1. Hemodynamic
Data.
Table 1Hemodynamic VariablesBefore
BalloonDuring
Balloon % of Change p Value1 Mean
RAP mmhg9.00 5.67 -37% 0.0052 s RVP mmHg 57.17 40.33 -30% 0.0033 Mean
PAP mmHg37.50 28.00 -26% 0.0434 Mean PWP
(mmhg)25.50 17.50 -32% 0.0165 CARDIAC
OUTPUT l/
min4.09 4.50 10% 0.157Statistical signiﬁcance was deﬁned as P < 0.05CONCLUSIONS We are reporting our hemodynamic and echocardio-
graphic experience in 6 patients with CHF treated with intermittent
reduction of preload with CCPB. Hemodynamic and echocardio-
graphic changes obtained in these patients, suggest, that this inno-
vative approach can play a role in the treatment of CHF patients.
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BACKGROUND The decision to intervene in severe aortic stenosis is
highly dependent on the patient’s symptoms and functional capacity.
Approximately 80% of patients with severe symptomatic aortic ste-
nosis who are high-risk operable candidates for surgical aortic valve
replacement (SAVR) are in functional class III or IV upon enrollment in
clinical trials. Among patients who are eligible for both procedures, a
recently published randomized controlled trial (RCT) found that
transcatheter aortic valve replacement (TAVR) is associated with a
higher New York Heart Association (NYHA) functional class at 1-year
as compared to SAVR. This ﬁnding was not observed in other RCTs.
We aimed to perform a meta-analysis of RCTs comparing heart failure
functional classiﬁcation following TAVR vs. SAVR.
METHODS Pubmed, EMBASE, Cochrane Central, and conference ab-
stracts were searched for RCTs that (1) directly compared TAVR to
SAVR in patients with severe symptomatic aortic valve stenosis and
(2) reported NYHA functional class outcomes in (3) a follow-up period
greater than 1 year. In studies with overlapping populations, only the
one with the largest sample size was included. Odds-ratios were
computed using random or ﬁxed-effects models. Heterogeneity was
examined with I2 statistics. Review Manager 5.1 was used for meta-
analysis statistics.
RESULTS Three RCTs with a total of 1,393 patients were included, of
whom 732 (52.5%) underwent TAVR. In a follow-up that ranged from 1
to 2 years, no signiﬁcant difference was observed between treatment
groups with regards to NYHA functional class IV (OR 0.55; 95% CI 0.23-
1.32; p¼0.18), functional class III or IV (OR 1.01; 95% CI 0.72-1.42;
p¼0.95), and functional class I (OR 0.86; 95% CI 0.55-1.36; p¼0.53).
CONCLUSIONS Our meta-analysis suggests that in patients with se-
vere symptomatic aortic stenosis who are eligible for surgery, TAVR is
as effective as SAVR for improvement in heart failure symptoms in a 1
to 2-year follow-up. Ongoing trials will provide insights as to long-
term results.
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